Sector ratings Monte Rosa Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX 01:08:07 05/09/2026 am IST			5-day change	1st Jan Change
13.88 ^USD	-3.51%		+4.11%	-11.16%

24/08	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
24/08	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
MONTE ROSA THERAPEUTICS, INC.	122.68Cr	-	BB	-	-
LONZA GROUP AG	5.03TCr		AAA
REVOLUTION MEDICINES, INC.	4.52TCr	-	B	-	-
IQVIA HOLDINGS INC.	4.47TCr		AAA
BEONE MEDICINES AG	4.12TCr		-
CELLTRION, INC.	3.31TCr		A
ASCENDIS PHARMA A/S	1.78TCr	-	-	-	-
MEDPACE HOLDINGS, INC.	1.66TCr		BBB
EUROFINS SCIENTIFIC SE	1.48TCr		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	1.4TCr		AA
ICON PUBLIC LIMITED COMPANY	1.26TCr		AAA
BIO-TECHNE CORPORATION	1.14TCr		AA
TEMPUS AI, INC.	1.17TCr		A		-
PHARMARON BEIJING CO., LTD.	1.08TCr		AA
ABIVAX	1.08TCr	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	966.03Cr	-	A	-	-
GENSCRIPT BIOTECH CORPORATION	1.01TCr		AA		-
PRAXIS PRECISION MEDICINES, INC.	991.58Cr	-	B	-	-
KYMERA THERAPEUTICS, INC.	975.19Cr	-	BBB	-	-
PROTAGONIST THERAPEUTICS, INC.	962.86Cr		BB		-
Average	1.93TCr		A
Weighted average by Cap.			A